**Interfering with Interferon in Lupus: Hitting the Sweet Spot with CNTO 6358**

**Background** The type I interferon (IFN-I) family of cytokines is thought to play a central role in the pathogenesis of systemic lupus erythematosus (SLE) and therapeutic approaches to down-modulate this pathway have demonstrated clinical efficacy. The IFN-I pathway is composed of multiple closely related IFN-α subtypes and single functional molecules for IFN-β, IFN-γ, IFN-κ, and IFN-ω. Some members of the IFN-I family are thought to contribute to SLE pathogenesis, while others may be more relevant for host defense. We developed a fully-human monoclonal antibody (CNTO 6358) to selectively neutralise the predominant soluble IFN-Is expressed in SLE, while retaining the functions of IFN-β. Here we demonstrate in vitro bioactivity using endogenous SLE patient-derived IFN-I preparations, including immune complexes and serum/plasma from racially diverse SLE populations, providing evidence that the neutralisation and potency profile of CNTO 6358 may enable potent suppression of IFN-Is prevalent in SLE without suppression of other IFN-Is more essential for other host defense processes. We further describe an in vitro assay that may enable the prediction of responders and non-responders with CNTO 6358, providing a transformational framework for SLE precision medicine.

**Materials and methods** Pooled SLE serum and plasma or conditioned media from cells exposed to pooled SLE patient immune complexes or recombinant human IFN-Is were utilised as stimuli in an in vitro reporter gene assay (RGA) in the presence of CNTO 6358 or control. SLE patient whole blood was incubated for 24 hours in the presence or absence of CNTO 6358 and the impact of inhibitor treatment on gene expression was determined by RNA-Seq relative to untreated healthy donor samples.

**Results** IFN-I activity present in plasma and serum preparations from multiple SLE cohorts and activity present in conditioned media from PBMCs exposed to SLE patient immune complexes was neutralised to levels seen in healthy control samples. The in vitro addition of CNTO 6358 to blood from individual SLE patients enabled the identification of donors having robust normalisation of baseline elevated IFN-I signature gene expression and those having moderate to minimal transcriptional changes. CNTO 6358 exhibited potent neutralisation of multiple SLE patient-derived IFN-I preparations, demonstrating a bioactivity profile targeting the most prevalent IFN-I subtypes elevated in SLE patients, while preserving the functionality of other IFN-Is which may be more important for host defense. Furthermore, our in vitro assay and in silico methodologies may enable prediction of responders to our treatment, providing a transformational framework for SLE precision medicine.

---

**Advanced Glycation End products (AGES) and Association with Systemic Lupus Erythematosus**

**Background** Oxidative stress plays a role in disease activity and premature atherosclerosis seen in patients with systemic lupus erythematosus (SLE). Advanced glycation end products (AGES) are prevalent in the Western diet. The accumulation of serum AGES disrupts protein function, and interaction with its receptor induces production of reactive oxygen species and activation of vascular endothelial cells, leading to increased oxidative stress. Our hypothesis is that serum AGE levels, indicators of dietary habits, correlate with inflammation and potentially impact autoimmunity.

**Materials and methods** We evaluated clinical data and serum samples from 80 Gullah African American participants enrolled prospectively into the SLE in Gullah Health (SLEIGH) study. Of the 80 participants, 50 were patients with SLE and 30 were unaffected controls (15 related controls and 15 unrelated controls). Serum samples were assessed with the AGE Competitive ELISA kit from Cell Bio Labs. All samples were normalised to total protein concentration.

**Results** Overall there were no significant differences in mean AGE levels between SLE patients (2.8 mcg/mL ± 1.8), related controls (5.0 mcg/mL ± 3.1) or unrelated controls (1.2 mcg/mL ± 0.6). Obese patients (BMI ≥ 30) had significantly higher AGE levels than non-obese patients (p = 0.03), though there was no difference among controls. Smoking history was associated with higher AGE levels (p = 0.03). Although on average higher, AGE levels were not significantly associated with diabetes, hyperlipidemia, or stroke history. There was no difference in mean AGE levels with presence of hypertension or current corticosteroid use. Regression models demonstrated no significant influence of AGE level on patient or control status (OR 0.93, p = NS), including when adjusted for gender, age (in years) and BMI. Interestingly, among controls, ANA positivity significantly correlated with higher AGE levels (p = 0.01), when adjusted for age (years).

**Conclusions** Although there was not a difference in AGE levels between SLE patients and controls, the AGE levels were higher with ANA positivity among controls. This finding suggests that serum AGE levels may play a role as a modifiable risk factor for autoimmunity and further study is warranted.

---

**Genetics, Genomics and Epigenetics**

**Characterisation of a CD3+CD4+CD28+CD11A*KIR*CD70*CD40L* T Cell Subset in Patients with Active Lupus**

Faith Strickland, Bruce Richardson*. University of Michigan, Ann Arbor MI, USA

**Background** Inhibiting DNA methylation in human or mouse CD4+ T cells causes overexpression of methylation sensitive genes including CD11a, CD70, CD40L and the killer-cell immunoglobulin-like receptor (KIR) gene family, and the epigenetically altered murine cells are sufficient to cause lupus-like...